Table:
Parameter	RA group (n = 82)	Control group (n = 87)	p value
Sex of subjects, n (% of group)
Female	61 (74.4%)	50 (57.5%)	0.0012
Male	21 (25.6%)	37 (42.5%)
Age (years), median (range)	54 (20–82)	53 (25–78)	NS
BMI (kg/m2), n (%)
<18.5	2 (2.4%)	2 (2.3%)	NS
18.5–24.9	36 (43.9%)	29 (33.3%)
≥25	44 (53.7%)	56 (64.4%)
Cigarette smoking, n (%)
Current smoker	22 (26.8%)	31 (35.6%)	0.023
Former smoker (cessation ≥ 1 year)	29 (35.4%)	38 (43.7%)
Never smoker	31 (37.8%)	18 (20.7%)
Albumin (g/dL), median (range)	3.93 (2.57–5.70)	4.23 (2.85–5.42)	<0.000001
Uric acid (g/dL), median (range)	4.3 (1.5–9.1)	5.2 (3.0–8.8)	NS
Time from RA onset (years), median (range)	8.5 (0.2–50)	—	—
RF + (cutoff 20 IU/mL), n (%)	53 (64.6%)	—	—
ACPA + (cutoff 25 U/mL), n (%)	41 (50.0%)	—	—
Number of swollen joints, median (range)	4 (0–24)	—	—
DAS 28, median (range)	5.01 (1.49–8.49)	—	—
Treatment	—
Methotrexate	46 (56.1%)	—	—
Other nonbiologic DMARDs	33 (40.2%)	—	—
Anti-TNF therapy	23 (28.0%)	—	—
Steroids	62 (75.6%)	—	—

Continue parse the figure with markdown style: | Parameter | RA group (n = 82) | Control group (n = 87) | p value | 
 | --- | --- | --- | --- | 
 | <COLSPAN=4> Sex of subjects, n (% of group) | 
 | Female | 61 (74.4%) | 50 (57.5%) | <ROWSPAN=2> 0.0012 | 
 | Male | 21 (25.6%) | 37 (42.5%) | 
 | Age (years), median (range) | 54 (20–82) | 53 (25–78) | NS | 
 | <COLSPAN=4> BMI (kg/m2), n (%) | 
 | <18.5 | 2 (2.4%) | 2 (2.3%) | <ROWSPAN=3> NS | 
 | 18.5–24.9 | 36 (43.9%) | 29 (33.3%) | 
 | ≥25

| 44 (53.7%) | 56 (64.4%) | 
 | <COLSPAN=4> Cigarette smoking, n (%) | 
 | Current smoker | 22 (26.8%) | 31 (35.6%) | <ROWSPAN=3> 0.023 | 
 | Former smoker (cessation ≥ 1 year) | 29 (35.4%) | 38 (43.7%) | 
 | Never smoker | 31 (37.8%) | 18 (20.7%) | 
 | Albumin (g/dL), median (range) | 3.93 (2.57–5.70) | 4.23 (2.85–5.42) | <0.000001 | 
 | Uric acid (g/dL), median (range) | 4.3 (1.5–9.1) | 5.2 (3.0–8.8) | NS | 
 | Time from RA onset (years), median (range) | 8.5 (0.2–50) | — | — | 
 | RF + (cutoff 20 IU/mL), n (%) | 53 (64.6%) | — | — | 
 | ACPA + (cutoff 25 U/mL), n (%) | 41 (50.0%) | — | — | 
 | Number of swollen joints, median (range) | 4 (0–24) | — | — | 
 | DAS 28, median (range) | 5.01 (1.49–8.49) | — | — | 
 | Treatment |  |  | — | 
 | Methotrexate | 46 (56.1%) | — | — | 
 | Other nonbiologic DMARDs | 33 (40.2%) | — | — | 
 | Anti-TNF therapy | 23 (28.0%) | — | — | 
 | Steroids | 62 (75.6%) | — | — |